Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy To Buy U.S. FDA-Approved Plants Outside Of India

This article was originally published in PharmAsia News

Executive Summary

Hampered by the U.S. FDA's rejection of 30 of its generic drugs because of two plants in which they were made, Ranbaxy Laboratories now plans to buy plants that already have the agency's approval. The plants have not been identified, but they could be in the United States or in other countries so the Indian drug maker can get its products back on the market, according to CEO Malvinder Singh. He said he expected to select the facilities by the end of the year, although production would be more expensive than at Ranbaxy's own Indian facilities. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts